How does the P&T committee anticipate new approvals will impact the atopic dermatitis treatment paradigm?
P&T Session Atopic Dermatitis: MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
© 2025 MMIT